Inclusion Criteria:  Male or female of non-childbearing potential (NCBP) Aged 18-55 years (both inclusive) at the time of signing informed consent Body mass index (BMI) between 27.0 and 39.9 kg/m^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator  Exclusion Criteria:  Previous participation in trial(s) with an amylin analogue unless documented that the subject was assigned to placebo treatment. Participation is defined as randomisation Any disorder which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol